Image Source: Unsplash
An Introduction
This article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week, in descending order, and MTD and their areas of focus, along with their latest news, analyses and commentary where available.
- **GH Research (GHRS): UP 8.7% last week; UP 30.4% MTD
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Latest news, commentary and/or analysis:
- *AbCellera Biologics (ABCL): UP 5.8% last week; UP 2.4% MTD
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Latest news, commentary and/or analysis:
- *Relay Therapeutics (RLAY): UP 2.7% last week; UP 7.1% MTD
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Latest news, commentary and/or analysis:
- **Mind Medicine (MNMD): UP 0.1% last week; DOWN 3.4% MTD
- *Recursion Pharmaceuticals (RXRX): DOWN 2.8% last week; UP 12.8% MTD
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Latest news, commentary and/or analysis:
- *Schrödinger (SDGR): DOWN 3.4% last week; DOWN 8.3% MTD
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Latest news, commentary and/or analysis:
- **Compass Pathways (CMPS): DOWN 4.6% last week; DOWN 5.8% MTD
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest news, commentary and/or analysis:
- **atai Life Sciences (ATAI): DOWN 5.8% last week; DOWN 16.6% MTD
- *Absci Corporation (ABSI): DOWN 8.9% last week; DOWN 8.1% MTD
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Latest news, commentary and/or analysis:
- *Exscientia (EXAI): DOWN 9.8% last week; UP 16.4% MTD
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Latest news, commentary and/or analysis:
Summary
On average, the above 10 stocks were DOWN 1.1% last week and are now DOWN 0.6% MTD and DOWN 11.7% YTD.
More By This Author:
AI Category Returns Were A Mixed Bag This Week
Update: Ai Pin Widely Panned; Humane Announces It's For Sale
These AI Stocks Have Momentum Up And Down
.webp)
Comments
Log in or sign up to join the conversation.